Company Filing History:
2 out of 512 
2 out of 20 
2 out of 560 
Years Active: 1982-2018
Title: Martin Fleisher: Innovator in Cancer Research
Introduction
Martin Fleisher is a notable inventor based in Glen Cove, NY, renowned for his contributions to cancer research through innovative methods related to gene expression and proteomic labeling. With a portfolio of six patents, Fleisher's work stands at the intersection of biology and technology, pushing the boundaries of what is possible in medical science.
Latest Patents
Fleisher's latest patents showcase his expertise in developing novel methodologies. One significant invention is focused on genes associated with dasatinib sensitivity, particularly through the Cell Type specific labeling with Amino acid Precursors (CTAP). This method enables the incorporation of stable isotope-labeled amino acids into the proteome of vertebrate cells engineered to produce essential amino acids from substrates. By employing labeled amino acid precursors, this technique supports cell growth and allows for specific protein labeling, facilitating detailed studies of multicellular environments.
Another remarkable patent involves the gene expression profile associated with prostate cancer. Utilizing an RT-PCR platform, Fleisher has developed a method to detect gene transcripts that are highly expressed in prostate tissue and in peripheral blood mononuclear cells (PBMC) from patients with metastatic castration-resistant prostate cancer (mCRPC). This method aims to provide a more robust prediction of overall survival compared to conventional CTC enumeration by identifying key genes associated with poor outcomes, including KLK3, KLK2, HOXB13, GHRL2, and FOXA1.
Career Highlights
Throughout his career, Martin Fleisher has made significant strides in the field of cancer research. His work has been influential in understanding the molecular underpinnings of cancer and in developing predictive tools that aid in patient management. He has been associated with prestigious institutions such as the Sloan Kettering Institute for Cancer Research and the Memorial Hospital for Cancer and Allied Diseases, where he has conducted advanced research in oncology.
Collaborations
Fleisher has worked alongside distinguished colleagues in the field, including Daniel C. Danila and Howard Scher. Their collaborative efforts have enhanced the impact of their research and resulted in breakthroughs that contribute to better patient outcomes in cancer treatment.
Conclusion
Martin Fleisher's innovative contributions to cancer research through his patents and collaborative efforts demonstrate his commitment to improving healthcare outcomes. With a focus on understanding gene expressions and developing novel labeling techniques, Fleisher continues to be an influential figure in the scientific community, paving the way for future advancements in cancer diagnostics and therapeutics.